Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07373743 · ClinicalTrials.gov registry record · Early Phase 1
Pharmacokinetic (PK) Study of Tafenoquine in Healthy Adults
A Early Phase 1 study, sponsored by State University of New York - Upstate Medical University.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT07373743 is a Early Phase 1 study that has not yet begun recruiting, run by State University of New York - Upstate Medical University. The registered enrollment target is 20 participants.
The verdict
NCT07373743, a Early Phase 1 study, has not yet begun recruiting, sponsored by State University of New York - Upstate Medical University.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn how people's different genetic makeups affects how their bodies convert the FDA approved drug ARAKODA (tafenoquine) to its active form. Tafenoquine is a drug that is taken to prevent malaria for people traveling to areas where there is malaria. This trial will be in healthy participants age 18-65.
Interventions
- DRUG Tafenoquine Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-05 |
| Est. Completion | 2027-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07373743
The ClinicalTrials.gov registry entry for NCT07373743 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York - Upstate Medical University, which has 113 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tafenoquine Oral Tablet is the first listed.
NCT07373743 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07373743 about?
NCT07373743 is a clinical study titled "Pharmacokinetic (PK) Study of Tafenoquine in Healthy Adults". The goal of this clinical trial is to learn how people's different genetic makeups affects how their bodies convert the FDA approved drug ARAKODA (tafenoquine) to its active form. Tafenoquine is a drug that is taken to prevent malaria for people traveling to areas where there is malaria. This trial ...
What is the current status of trial NCT07373743?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2026-05. Estimated completion is 2027-03.
What interventions are being tested in trial NCT07373743?
The interventions under investigation include: Tafenoquine Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT07373743?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.